[Efficacy and tolerance of bevacizumab in non-small cell lung cancer: preliminary report]

Abstract

Introduction: Bevacizumab is an antiangiogenic drug targeting VEGF. Its interest, in combination with chemotherapy, has been demonstrated in two recent trials in metastatic non-small cell lung cancer and its approval is awaited within few weeks. Due its original mechanism of action, bevacizumab has a very specific safety profile and radiological response patterns.

Method: Based upon selected observations reported from patients included in clinical trials and on recent literature, we bring some clue for a better and safer use of bevacizumab.

Results: We report toxicity associated with bevacizumab, especially vascular side-effects and unusual radiological responses.

Conclusion: Bevacizumab use in NSCLC is associated with some unexpected side effects and responses that worth to be known by pulmonologists. Selections criteria should be rigorously followed.